|
| Autoimmune disease |
| Type 1 diabetes |
| (i) Pancreatic lymph node DC (untreated) [1] |
| (ii) Mature bone-marrow-derived DC (GM-CSF/IL-4 propagated) or transduced with IL-4 vector [2–4], or TGFbeta [5] |
| (iii) NF-kappaB oligonucleotide decoy propagated or NF-kappaB inhibition [6, 7] |
| (iv) Antisense oligonucleotide (CD40-, CD80-, CD86-) propagated [8] |
| (v) Vitamin D receptor ligands [9, 10] |
| (vi) Other DC embodiments [11–16] |
| Thyroiditis |
| (i) In vitro generation with TNFa and supernatant of a GM-CSF-transduced cell line [17, 18] |
| (ii) GM-CSF generated followed by in vivo administration of GM-CSF [19] |
| Experimental encephalomyelitis (Multiple sclerosis model) |
| (i) In vitro generation with TNFa and supernatant of a GM-CSF-transduced cell line [17, 18] |
| (ii) VIP and GM-CSF in vitro propagation [20, 21] |
| (iii) TGFbeta and MBP antigen [22] |
| Myasthenia gravis |
| (i) RelB knockdown [23] |
| Arthritis |
| (i) VIP and GM-CSF in vitro propagation [20, 21] |
| (ii) IL-4- or IL-10-expressing bone-marrow-derived DC and derivative exosome preparations [24–26] |
| (iii) CD95- (Fas ligand-) expressing bone marrow-derived DC [27, 28] |
| Gastritis |
| (i) IL-10- expressing DC [29] |
| Allergy/asthma |
| (i) IL-10- overexpressing vector [30] |
| (ii) Allergen overexpression [31] |
|
| Allotransplantation/xenotransplantation |
| Administration of bone-marrow-derived DC from transplant organ donor |
| (i) DC propagated in low-concentration GM-CSF [32–34] |
| (ii) DC propagated in GM-CSF, IL-10, TGFb and matured with LPS [35] |
| (iii) In vitro blockade of NF-kappaB by adding aspirin, vitamin D3 metabolites/analogues, glucosamine, N-acetyl-cysteine, corticosteroids, cyclosporin A, rapamycin, deoxyspergualin, and mycophenolate mofetil [36–51] |
| (iv) Gene engineering in vitro; DC expressing IL-10, TGFbeta, CTLA-4Ig, indolamine-2,3 dioxygenase, Fas-ligand [52–60] |
| Administration of transplant-recipient-derived DC prior to transplantation |
| (i) DC pulsed with class I MHC allopeptide or other alloantigens [61, 62] |
| (ii) Rapamycin and donor tissue lysate [63] |
|
